Literature DB >> 3423823

Pheochromocytoma presenting as musculoskeletal pain from bone metastases.

M D Lynn1, E M Braunstein, B Shapiro.   

Abstract

Six patients presented with musculoskeletal pain resulting from destructive bone lesions. These patients were ultimately shown to have metastatic pheochromocytoma. None of the cases exhibited typical symptoms of metastatic pheochromocytoma, nor was it suspected at the time of presentation. In three patients, hypertension caused pheochromocytoma to be considered as a diagnosis. The three remaining patients, all of whom had documented hypertension in the past, underwent bone biopsy. Two of these patients became markedly hypertensive in the postoperative period. Malignant pheochromocytoma may present with metastatic skeletal disease in some patients in whom the presence of hypertension as well as a carefully elicited history may suggest the diagnosis. In such patients, the possibility of pheochromocytoma should be taken into account, as biopsy may trigger a hypertensive crisis in patients not under adrenergic blockade.

Entities:  

Mesh:

Year:  1987        PMID: 3423823     DOI: 10.1007/BF00351270

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  15 in total

1.  The estimation of catechol amines in urine.

Authors:  U von EULER; F LISHAJKO
Journal:  Acta Physiol Scand       Date:  1959-03-31

2.  Malignant pheochromocytoma: clinical course and treatment.

Authors:  E M Mahoney; J H Harrison
Journal:  J Urol       Date:  1977-08       Impact factor: 7.450

3.  Phaeochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results.

Authors:  I M Modlin; J R Farndon; A Shepherd; I D Johnston; T L Kennedy; D A Montgomery; R B Welbourn
Journal:  Br J Surg       Date:  1979-07       Impact factor: 6.939

Review 4.  Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors.

Authors:  A J McEwan; B Shapiro; J C Sisson; W H Beierwaltes; D M Ackery
Journal:  Semin Nucl Med       Date:  1985-04       Impact factor: 4.446

5.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

6.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.

Authors:  E L Bravo; R C Tarazi; R W Gifford; B H Stewart
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

7.  Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterization.

Authors:  B Shapiro; J C Sisson; R Lloyd; M Nakajo; W Satterlee; W H Beierwaltes
Journal:  Clin Endocrinol (Oxf)       Date:  1984-02       Impact factor: 3.478

8.  Bone metastases in pheochromocytoma: comparative studies of efficacy of imaging.

Authors:  M D Lynn; E M Braunstein; R L Wahl; B Shapiro; M D Gross; R Rabbani
Journal:  Radiology       Date:  1986-09       Impact factor: 11.105

9.  Pheochromocytoma. A persistently problematic and still potentially lethal disease.

Authors:  D T Freier; F E Eckhauser; T S Harrison
Journal:  Arch Surg       Date:  1980-04

10.  Complementary roles of CT and 131I-MIBG scintigraphy in diagnosing pheochromocytoma.

Authors:  I R Francis; G M Glazer; B Shapiro; J C Sisson; B H Gross
Journal:  AJR Am J Roentgenol       Date:  1983-10       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.